In This Issue: Ireland recorded 10,600 abortions in 2025, a 59.02% increase from 6,666 in 2019, the first-year abortion on demand became legal. The latest figures bring the total number of abortions since legalization to nearly 60,000.
In This Issue: Planned Parenthood, the nation’s largest abortion provider, has resumed billing Medicaid for non-abortion services after nearly a year without federal reimbursements. The organization has claimed that the funding cut contributed to the closure of nearly 30 of its roughly 600 clinics, along with a 25% decline in birth control distribution and a 20% drop in breast cancer screenings.
In This Issue: A new peer-reviewed study from the Charlotte Lozier Institute found significant gaps in informed consent for women undergoing chemical abortions. Researchers analyzed 179 narratives from online media and surveyed 362 women who had taken abortion drugs within the past five years. 30% of women reported experiencing more pain and bleeding than expected, while many sought information online about abortion side effects and emotional distress.
In This Issue: Two new studies have linked smartphones to plunging birthrates. In the U.S., the iPhone rollout in 2007 coincided with falling fertility rates, and counties with early AT&T coverage saw the sharpest declines. The most pronounced effects were among those ages 15 to 24, accounting for as much as half of the 2007–2011 drop.
In This Issue: In an effort to combat its deepening demographic crisis, Japan’s Kochi Prefecture is offering subsidies of up to 20,000 yen (roughly $125) to singles ages 20–39 to use dating and matchmaking services. The move comes as births fell to a record low of 705,809 in 2025, marking a 10th consecutive year of decline.
In This Issue: The Congressional Budget Office now projects that U.S. deaths will outnumber births by 2030, a decade earlier than previously expected—a trend that will only worsen in the decades ahead. Future U.S. population growth will increasingly rely on immigration.
In This Issue: New figures from the Department of Health and Social Care show disability-selective abortions in England and Wales rose 2.59% in 2023, with 3,205 unborn children aborted due to diagnosed disabilities. This included 685 abortions for Down syndrome and 300 late-term abortions at 24 weeks or beyond, a 17.19% increase from the previous year.
In This Issue: The Trump administration announced it is ending all NIH funding for research using tissue from aborted babies, effective immediately. The policy applies across all NIH grants and programs, expanding on Trump’s first-term ban on intramural fetal tissue research. NIH Director Jay Bhattacharya said ethical alternatives now make such research unnecessary.
In This Issue: The European Parliament has voted to advance a proposal that would use EU taxpayer funds to pay for abortions abroad for women from countries with pro-life laws, including Poland and Malta. The nonbinding measure passed 358 to 202 and would override national protections by encouraging abortion tourism across member states. The scheme undermines national sovereignty, parental protections, and Europe’s Christian moral heritage.
In This Issue: The FDA, under Trump appointee Dr. Marty Makary, has approved new generic abortion pills made by Evita Solution, a company that openly seeks to “normalize abortion” and make it “accessible to all.” Despite promises of a full safety review of the chemical abortion drug, the FDA instead fast-tracked approval, prompting outrage from U.S. Sen. Josh Hawley.
In This Issue: Ireland recorded 10,600 abortions in 2025, a 59.02% increase from 6,666 in 2019, the first-year abortion on demand became legal. The latest figures bring the total number of abortions since legalization to nearly 60,000.
In This Issue: Planned Parenthood, the nation’s largest abortion provider, has resumed billing Medicaid for non-abortion services after nearly a year without federal reimbursements. The organization has claimed that the funding cut contributed to the closure of nearly 30 of its roughly 600 clinics, along with a 25% decline in birth control distribution and a 20% drop in breast cancer screenings.
In This Issue: A new peer-reviewed study from the Charlotte Lozier Institute found significant gaps in informed consent for women undergoing chemical abortions. Researchers analyzed 179 narratives from online media and surveyed 362 women who had taken abortion drugs within the past five years. 30% of women reported experiencing more pain and bleeding than expected, while many sought information online about abortion side effects and emotional distress.
In This Issue: Two new studies have linked smartphones to plunging birthrates. In the U.S., the iPhone rollout in 2007 coincided with falling fertility rates, and counties with early AT&T coverage saw the sharpest declines. The most pronounced effects were among those ages 15 to 24, accounting for as much as half of the 2007–2011 drop.
In This Issue: In an effort to combat its deepening demographic crisis, Japan’s Kochi Prefecture is offering subsidies of up to 20,000 yen (roughly $125) to singles ages 20–39 to use dating and matchmaking services. The move comes as births fell to a record low of 705,809 in 2025, marking a 10th consecutive year of decline.
In This Issue: The Congressional Budget Office now projects that U.S. deaths will outnumber births by 2030, a decade earlier than previously expected—a trend that will only worsen in the decades ahead. Future U.S. population growth will increasingly rely on immigration.
In This Issue: New figures from the Department of Health and Social Care show disability-selective abortions in England and Wales rose 2.59% in 2023, with 3,205 unborn children aborted due to diagnosed disabilities. This included 685 abortions for Down syndrome and 300 late-term abortions at 24 weeks or beyond, a 17.19% increase from the previous year.
In This Issue: The Trump administration announced it is ending all NIH funding for research using tissue from aborted babies, effective immediately. The policy applies across all NIH grants and programs, expanding on Trump’s first-term ban on intramural fetal tissue research. NIH Director Jay Bhattacharya said ethical alternatives now make such research unnecessary.
In This Issue: The European Parliament has voted to advance a proposal that would use EU taxpayer funds to pay for abortions abroad for women from countries with pro-life laws, including Poland and Malta. The nonbinding measure passed 358 to 202 and would override national protections by encouraging abortion tourism across member states. The scheme undermines national sovereignty, parental protections, and Europe’s Christian moral heritage.
In This Issue: The FDA, under Trump appointee Dr. Marty Makary, has approved new generic abortion pills made by Evita Solution, a company that openly seeks to “normalize abortion” and make it “accessible to all.” Despite promises of a full safety review of the chemical abortion drug, the FDA instead fast-tracked approval, prompting outrage from U.S. Sen. Josh Hawley.